healthcare

professional

SURPASS-1

SURPASS-1

Efficacy and Safety of Novel dual GIP and GLP-1 receptor against tirzepatide in patients with Type 2 Diabetes

+ read more

SURPASS-2

SURPASS-2

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

+ read more

SURMOUNT 1

SURMOUNT 1

Tirzepatide once weekly for the treatment of obesity

+ read more
Scroll to Top